RedHill Biopharma Ltd.
RDHL
$2.07
-$0.065-3.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.74M | 2.74M | 1.29M | 1.29M | 567.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.74M | 2.74M | 1.29M | 1.29M | 567.50K |
| Cost of Revenue | 894.00K | 894.00K | 702.00K | 702.00K | 520.50K |
| Gross Profit | 1.84M | 1.84M | 584.00K | 584.00K | 47.00K |
| SG&A Expenses | 3.28M | 3.28M | 4.48M | 4.48M | 6.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -535.50K |
| Total Operating Expenses | 4.64M | 4.64M | 5.51M | 5.51M | 6.59M |
| Operating Income | -1.90M | -1.90M | -4.22M | -4.22M | -6.02M |
| Income Before Tax | -2.59M | -2.59M | -1.54M | -1.54M | -13.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.59M | -2.59M | -1.54M | -1.54M | -13.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.59M | -2.59M | -1.54M | -1.54M | -13.54M |
| EBIT | -1.90M | -1.90M | -4.22M | -4.22M | -6.02M |
| EBITDA | -1.88M | -1.82M | -4.02M | -4.02M | -5.84M |
| EPS Basic | -20.10K | -20.10K | -13.13K | -13.13K | -346.86K |
| Normalized Basic EPS | -0.68 | -0.68 | -0.82 | -0.82 | -20.49 |
| EPS Diluted | -20.10K | -20.10K | -13.13K | -13.13K | -346.86K |
| Normalized Diluted EPS | -0.68 | -0.68 | -0.82 | -0.82 | -20.49 |
| Average Basic Shares Outstanding | 1.29M | 1.29M | 1.18M | 1.18M | 390.50K |
| Average Diluted Shares Outstanding | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |